Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Insulin resistance7794 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00004 | 35258780 | Chin J Integr Med | Protective Roles of Shilajit in Modulating Resistin, Adiponectin, and Cytokines in Rats with Non-alcoholic Fatty Liver Disease. | 2022 | Details |
| A00009 | 35256195 | Thromb Res | Impaired fibrinolysis without hypercoagulability characterises patients with non-alcoholic fatty liver disease. | 2022 | Details |
| A00010 | 35255811 | BMC Gastroenterol | The effect of daily consumption of probiotic yogurt on liver enzymes, steatosis and fibrosis in patients with nonalcoholic fatty liver disease (NAFLD): study protocol for a randomized clinical trial. | 2022 | Details |
| A00014 | 35254877 | Arch Physiol Biochem | Resveratrol attenuates against high-fat-diet-promoted non-alcoholic fatty liver disease in rats mainly by targeting the miR-34a/SIRT1 axis. | 2022 | Details |
| A00023 | 35251371 | Dis Markers | Dose-Response Associations of Metabolic Score for Insulin Resistance Index with Nonalcoholic Fatty Liver Disease among a Nonobese Chinese Population: Retrospective Evidence from a Population-Based Cohort Study. | 2022 | Details |
| A00029 | 35250856 | Front Endocrinol (Lausanne) | Not Enough Fat: Mouse Models of Inherited Lipodystrophy. | 2022 | Details |
| A00031 | 35250588 | Front Pharmacol | Platelets in Non-alcoholic Fatty Liver Disease. | 2022 | Details |
| A00034 | 35249505 | Curr Drug Saf | Pioglitazone, Bladder Cancer and the Presumption of Innocence. | 2022 | Details |
| A00041 | 35247611 | Mol Metab | Serum Amyloid A1 Exacerbates Hepatic Steatosis via TLR4 Mediated NF-κB Signaling Pathway. | 2022 | Details |
| A00054 | 35241921 | J Inflamm Res | Reduction of Hepatic Steatosis, Oxidative Stress, Inflammation, Ballooning and Insulin Resistance After Therapy with Safranal in NAFLD Animal Model: A New Approach. | 2022 | Details |
| A00056 | 35240344 | Cell Mol Gastroenterol Hepatol | Activation of Liver mTORC1 Protects Against NASH via Dual Regulation of VLDL-TAG Secretion and De Novo Lipogenesis. | 2022 | Details |
| A00057 | 35238939 | J Clin Endocrinol Metab | Long or Irregular Menstrual Cycles and Risk of Prevalent and Incident Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A00059 | 35238641 | Proc Natl Acad Sci U S A | Disruption of the circadian clock component BMAL1 elicits an endocrine adaption impacting on insulin sensitivity and liver disease. | 2022 | Details |
| A00085 | 35226250 | Cell Biol Toxicol | AS3MT facilitates NLRP3 inflammasome activation by m6A modification during arsenic-induced hepatic insulin resistance. | 2022 | Details |
| A00089 | 35223701 | Front Pediatr | Association Between Non-invasive Diagnostic Methods of Liver Fibrosis and Type 2 Diabetes in Pediatric Patients With Non-alcoholic Fatty Liver Disease. | 2022 | Details |
| A00091 | 35222903 | Ther Adv Chronic Dis | Nicotinamide supplementation in diabetic nonalcoholic fatty liver disease patients: randomized controlled trial. | 2022 | Details |
| A00093 | 35222075 | Front Physiol | MicroRNA-122-5p Inhibition Improves Inflammation and Oxidative Stress Damage in Dietary-Induced Non-alcoholic Fatty Liver Disease Through Targeting FOXO3. | 2022 | Details |
| A00103 | 35218234 | Hepatology | Dual roles of B lymphocytes in murine models of diet-induced non-alcoholic fatty liver disease. | 2022 | Details |
| A00114 | 35216326 | Int J Mol Sci | New Insights in the Control of Fat Homeostasis: The Role of Neurotensin. | 2022 | Details |
| A00115 | 35216174 | Int J Mol Sci | Whole Body Ip6k1 Deletion Protects Mice from Age-Induced Weight Gain, Insulin Resistance and Metabolic Dysfunction. | 2022 | Details |
| A00125 | 35212998 | Methods Mol Biol | Analysis of Insulin Resistance in Nonalcoholic Steatohepatitis. | 2022 | Details |
| A00140 | 35212643 | Eur J Endocrinol | Increased liver fat associates with severe metabolic perturbations in low birth weight men. | 2022 | Details |
| A00150 | 35208229 | Metabolites | The Role of Aspartate Transaminase to Platelet Ratio Index (APRI) for the Prediction of Non-Alcoholic Fatty Liver Disease (NAFLD) in Severely Obese Children and Adolescents. | 2022 | Details |
| A00157 | 35204710 | Biomolecules | Posttranscriptional Regulation of Insulin Resistance: Implications for Metabolic Diseases. | 2022 | Details |
| A00158 | 35204522 | Diagnostics (Basel) | A Comparative Study of the Triglycerides/HDL Ratio and Pseudocholinesterase Levels in Patients with Bladder Cancer. | 2022 | Details |
| A00160 | 35204232 | Antioxidants (Basel) | Dietary Selenium Alleviated Mouse Liver Oxidative Stress and NAFLD Induced by Obesity by Regulating the KEAP1/NRF2 Pathway. | 2022 | Details |
| A00163 | 35203662 | Biomedicines | The Concept of Indeterminable NASH Inducted by Preoperative Diet and Metabolic Surgery: Analyses of Histopathological and Clinical Features. | 2022 | Details |
| A00170 | 35202771 | Diabetes Res Clin Pract | Dapagliflozin for nonalcoholic fatty liver disease: A systematic review and meta-analysis. | 2022 | Details |
| A00174 | 35198905 | iScience | Deletion of RNF186 expression suppresses diet-induced hepatic steatosis by regulating insulin activity. | 2022 | Details |
| A00183 | 35195377 | Minerva Endocrinol (Torino) | Inflammation is associated with impairment of oxidative status, carbohydrate and lipid metabolism in type 2 diabetes complicated by non-alcoholic fatty liver disease. | 2022 | Details |
| A00195 | 35190696 | Acta Pharmacol Sin | Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis. | 2022 | Details |
| A00208 | 35185803 | Front Endocrinol (Lausanne) | Single Point Insulin Sensitivity Estimator in Pediatric Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A00209 | 35185113 | J Pediatr Gastroenterol Nutr | Comparison of the Lipidomic Signature of Fatty Liver in Children and Adults: A Cross-Sectional Study. | 2022 | Details |
| A00212 | 35183303 | Lancet Diabetes Endocrinol | A global view of the interplay between non-alcoholic fatty liver disease and diabetes. | 2022 | Details |
| A00225 | 35176709 | Biomed Pharmacother | Purendan alleviates non-alcoholic fatty liver disease in aged type 2 diabetic rats via regulating mTOR/S6K1/SREBP-1c signaling pathway. | 2022 | Details |
| A00232 | 35173677 | Front Endocrinol (Lausanne) | Validation of Controlled Attenuation Parameter Measured by FibroScan as a Novel Surrogate Marker for the Evaluation of Metabolic Derangement. | 2022 | Details |
| A00244 | 35169195 | Sci Rep | Relationship between the dynamics of non-alcoholic fatty liver disease and incident diabetes mellitus. | 2022 | Details |
| A00246 | 35167495 | JCI Insight | Ethnic and gender differences in hepatic lipid content and related cardiometabolic parameters in lean individuals. | 2022 | Details |
| A00248 | 35166723 | Clin Transl Gastroenterol | Relationship between hepatic gene expression, intestinal microbiota and inferred functional metagenomic analysis in NAFLD. | 2022 | Details |
| A00253 | 35164140 | Molecules | A Comparison of the Gene Expression Profiles of Non-Alcoholic Fatty Liver Disease between Animal Models of a High-Fat Diet and Methionine-Choline-Deficient Diet. | 2022 | Details |
| A00258 | 35163521 | Int J Mol Sci | The Regulatory Role of the Central and Peripheral Serotonin Network on Feeding Signals in Metabolic Diseases. | 2022 | Details |
| A00266 | 35160329 | J Clin Med | Influence of Body Mass Index, Cancer Type and Treatment on Long-Term Metabolic and Liver Outcomes in Childhood Cancer Survivors. | 2022 | Details |
| A00268 | 35160087 | J Clin Med | Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A00279 | 35154005 | Front Endocrinol (Lausanne) | Novel Subgroups and Chronic Complications of Diabetes in Middle-Aged and Elderly Chinese:A Prospective Cohort Study. | 2022 | Details |
| A00291 | 35150905 | Mol Metab | ITCH E3 ubiquitin ligase downregulation compromises hepatic degradation of branched-chain amino acids. | 2022 | Details |
| A00300 | 35145074 | Nat Commun | Small molecule SWELL1 complex induction improves glycemic control and nonalcoholic fatty liver disease in murine Type 2 diabetes. | 2022 | Details |
| A00304 | 35144052 | Redox Biol | The role of selenium in type-2 diabetes mellitus and its metabolic comorbidities. | 2022 | Details |
| A00306 | 35143562 | PLoS One | Rural-Urban differentials in prevalence, spectrum and determinants of Non-alcoholic Fatty Liver Disease in North Indian population. | 2022 | Details |
| A00319 | 35138995 | Pharm Biol | Jinlida granules ameliorate the high-fat-diet induced liver injury in mice by antagonising hepatocytes pyroptosis. | 2022 | Details |
| A00335 | 35130757 | Biol Res Nurs | Effect of Aerobic Exercise Alone or in Conjunction With Diet on Liver Function, Insulin Resistance and Lipids in Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A00346 | 35126843 | World J Hepatol | Is there a role of lipid-lowering therapies in the management of fatty liver disease? | 2022 | Details |
| A00348 | 35126113 | Front Pharmacol | Fenofibrate Improves Insulin Resistance and Hepatic Steatosis and Regulates the Let-7/SERCA2b Axis in High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease Mice. | 2022 | Details |
| A00363 | 35119232 | J Basic Clin Physiol Pharmacol | Is it possible to treat nonalcoholic liver disease using a flavanol-based nutraceutical approach? Basic and clinical data. | 2022 | Details |
| A00372 | 35114586 | Biochem Biophys Res Commun | Estrogen receptor α mediated M1/M2 macrophages polarization plays a critical role in NASH of female mice. | 2022 | Details |
| A00378 | 35111461 | Cureus | Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD). | 2021 | Details |
| A00387 | 35107488 | Arq Bras Cir Dig | OBESITY AND SEVERE STEATOSIS: THE IMPORTANCE OF BIOCHEMICAL EXAMS AND SCORES. | 2022 | Details |
| A00388 | 35106510 | Cell Rep Med | Pegylated arginine deiminase drives arginine turnover and systemic autophagy to dictate energy metabolism. | 2022 | Details |
| A00392 | 35103461 | Minerva Endocrinol (Torino) | Akkermansia muciniphila as a novel powerful bacterial player in the treatment of metabolic disorders. | 2022 | Details |
| A00394 | 35102183 | Sci Rep | Intergenerational effects of preconception opioids on glucose homeostasis and hepatic transcription in adult male rats. | 2022 | Details |
| A00420 | 35091821 | Diabetologia | Adiponectin deficiency induces hepatic steatosis during pregnancy and gestational diabetes in mice. | 2022 | Details |
| A00429 | 35087411 | Front Pharmacol | Aurantio-Obtusin Attenuates Non-Alcoholic Fatty Liver Disease Through AMPK-Mediated Autophagy and Fatty Acid Oxidation Pathways. | 2022 | Details |
| A00447 | 35079935 | Mol Biol Rep | Physiological significance of bistable circuit design in metabolic homeostasis: role of integrated insulin-glucagon signalling network. | 2022 | Details |
| A00455 | 35075592 | Hepatol Int | Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice. | 2022 | Details |
| A00458 | 35074921 | Proc Natl Acad Sci U S A | Myeloid cell TBK1 restricts inflammatory responses. | 2022 | Details |
| A00459 | 35072848 | Inflammopharmacology | The effects of metformin, pioglitazone, exenatide and exercise on fatty liver in obese diabetic rats: the role of IRS-1 and SOCS-3 molecules. | 2022 | Details |
| A00477 | 35068225 | Exp Biol Med (Maywood) | Impact of spexin on metabolic diseases and inflammation: An updated minireview. | 2022 | Details |
| A00479 | 35067233 | Nutr Res Rev | MITOCHONDRIAL DYSFUNCTION AND EPIGENETICS UNDERLYING THE LINK BETWEEN EARLY-LIFE NUTRITION AND NON-ALCOHOLIC FATTY LIVER DISEASE. | 2022 | Details |
| A00488 | 35064452 | Indian J Gastroenterol | Screening for non-alcoholic fatty liver disease among obese and overweight children: Prevalence and predictors. | 2022 | Details |
| A00497 | 35061559 | Arch Physiol Biochem | Salidroside inhibits insulin resistance and hepatic steatosis by downregulating miR-21 and subsequent activation of AMPK and upregulation of PPARα in the liver and muscles of high fat diet-fed rats. | 2022 | Details |
| A00503 | 35059041 | Dis Markers | Pentraxin 3 and the TyG Index as Two Novel Markers to Diagnose NAFLD in Children. | 2021 | Details |
| A00506 | 35058529 | Sci Rep | Pcyt2 deficiency causes age-dependant development of nonalcoholic steatohepatitis and insulin resistance that could be attenuated with phosphoethanolamine. | 2022 | Details |
| A00516 | 35054924 | Int J Mol Sci | GLP-1a: Going beyond Traditional Use. | 2022 | Details |
| A00522 | 35053629 | Children (Basel) | Cardiovascular Risk Factors and Subclinical Atherosclerosis in Greek Adolescents with Polycystic Ovary Syndrome: Its Relationship with Body Mass Index. | 2021 | Details |
| A00529 | 35052872 | Biomedicines | Detailed Molecular Mechanisms Involved in Drug-Induced Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: An Update. | 2022 | Details |
| A00532 | 35052811 | Biomedicines | Prevalence, Risk Factors, and Pathophysiology of Nonalcoholic Fatty Liver Disease (NAFLD) in Women with Polycystic Ovary Syndrome (PCOS). | 2022 | Details |
| A00535 | 35052736 | Biomedicines | Differential iNKT and T Cells Activation in Non-Alcoholic Fatty Liver Disease and Drug-Induced Liver Injury. | 2021 | Details |
| A00544 | 35052547 | Antioxidants (Basel) | Preventive Effects of β-Cryptoxanthin, a Potent Antioxidant and Provitamin A Carotenoid, on Lifestyle-Related Diseases-A Central Focus on Its Effects on Non-Alcoholic Fatty Liver Disease (NAFLD). | 2021 | Details |
| A00548 | 35050189 | Metabolites | The Role of Fructose as a Cardiovascular Risk Factor: An Update. | 2022 | Details |
| A00549 | 35050187 | Metabolites | The Interaction between the Gut Microbiome and Bile Acids in Cardiometabolic Diseases. | 2022 | Details |
| A00553 | 35048271 | Mol Biol Rep | Hepatic microRNA modulation might be an early event to non-alcoholic fatty liver disease development driven by high-fat diet in male mice. | 2022 | Details |
| A00589 | 35038311 | Eur J Endocrinol | Metformin maintains intrahepatic triglyceride content through increased hepatic de novo lipogenesis. | 2022 | Details |
| A00595 | 35035496 | Evid Based Complement Alternat Med | Lanzhang Granules Ameliorate Nonalcoholic Fatty Liver Disease by Regulating the PPARα Signaling Pathway. | 2022 | Details |
| A00614 | 35028615 | Cell Rep Med | Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study. | 2021 | Details |
| A00621 | 35024735 | Rom J Morphol Embryol | Triglyceride and glucose index: a useful tool for non-alcoholic liver disease assessed by liver biopsy in patients with metabolic syndrome? | 2022 | Details |
| A00634 | 35021057 | Immunity | Inflammation in obesity, diabetes, and related disorders. | 2022 | Details |
| A00645 | 35016619 | BMC Geriatr | Is there an association between non-alcoholic fatty liver disease and cognitive function? A systematic review. | 2022 | Details |
| A00648 | 35015002 | Food Funct | Higher serum vitamin A is associated with a worsened progression of non-alcoholic fatty liver disease in adults: a prospective study. | 2022 | Details |
| A00651 | 35014161 | Diabetes Obes Metab | The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment. | 2022 | Details |
| A00653 | 35014145 | Diabetes Obes Metab | Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT). | 2022 | Details |
| A00659 | 35011784 | J Clin Med | Triglyceride Glucose-Waist Circumference Is Superior to the Homeostasis Model Assessment of Insulin Resistance in Identifying Nonalcoholic Fatty Liver Disease in Healthy Subjects. | 2021 | Details |
| A00665 | 35010950 | Nutrients | Sulforaphane Attenuates Nonalcoholic Fatty Liver Disease by Inhibiting Hepatic Steatosis and Apoptosis. | 2021 | Details |
| A00668 | 35009003 | Int J Mol Sci | Heat Shock Protein 60 Restricts Release of Mitochondrial dsRNA to Suppress Hepatic Inflammation and Ameliorate Non-Alcoholic Fatty Liver Disease in Mice. | 2022 | Details |
| A00669 | 35008925 | Int J Mol Sci | Non-Alcoholic Steatohepatitis (NASH) and Organokines: What Is Now and What Will Be in the Future. | 2022 | Details |
| A00671 | 35008682 | Int J Mol Sci | Emerging Roles of Calcium Signaling in the Development of Non-Alcoholic Fatty Liver Disease. | 2021 | Details |
| A00682 | 35004947 | Hepatobiliary Surg Nutr | The presence of NAFLD in nonobese subjects increased the risk of metabolic abnormalities than obese subjects without NAFLD: a population-based cross-sectional study. | 2021 | Details |
| A00696 | 34999396 | Int Immunopharmacol | Liensinine alleviates high fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD) through suppressing oxidative stress and inflammation via regulating TAK1/AMPK signaling. | 2022 | Details |
| A00709 | 34993389 | Curr Dev Nutr | Considerations When Choosing High-Fat, High-Fructose, and High-Cholesterol Diets to Induce Experimental Nonalcoholic Fatty Liver Disease in Laboratory Animal Models. | 2021 | Details |
| A00724 | 34988690 | Acta Diabetol | Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: A network meta-analysis. | 2022 | Details |
| A00725 | 34988225 | Biomed Res Int | Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis. | 2021 | Details |
| A00739 | 34983354 | Endocr Metab Immune Disord Drug Targets | Increasing risk factors of non-alcoholic fatty liver disease, a look into chronic periodontitis and insulin resistance. | 2022 | Details |